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Triple-negative breast cancer (TNBC), is a specific subtype of epithelial breast
tumors that are immuno-histochemically negative for the protein expression of the
estrogen receptor (ER), the progesterone receptor (PR) and lack over expression/gene
amplification of HER2. This subtype of breast cancers is highly metastatic, shows
poor prognosis and hence represents an important clinical challenge to researchers
worldwide. Thus alternative approaches of drug development for TNBC have gained
utmost importance in the present times. Dietary indole and its derivatives have
gained prominence as anti-cancer agents and new therapeutic approaches are being
developed to target them against TNBC. But a major drawback with 3, 3′di Indolyl
methane (DIM) is their poor bioavailability and high effective concentration against
TNBC. However, the Aryl methyl ring substituted analogs of DIM display interesting anti-
cancer activity in breast cancer cells. In the current study we report the synthesis of
a novel synthetic aryl methyl ring substituted analog of DIM, named as Phemindole
as an effective anti-tumor agent against TNBC cells. Furthermore, we enumerated
that Phemindole caused reactive oxygen species mediated mitochondrial-dependent
apoptosis in MDAMB-231 cells. Furthermore, Phemindole mediated Store Operated
Calcium Entry (SOCE) retardation favored inactivation of STIM1 and henceforth activated
ER stress to induce apoptosis in TNBC cells. Simultaneously, Phemindole was also
found to restrict the in vitro cell migration through its anti mitotic property and pFAK
regulation. Studies extended to ex ovo and in vivo mice models further validated the
efficacy of Phemindole. Thus our results cumulatively propose Phemindole as a new
chemotherapeutic regime which might be effective to target the deadly aspects of the
TNBC.
Keywords: Phemindole, triple negative breast cancer (TNBC), stromal interaction molecule1 (STIM1), store-
operated calcium entry (SOCE), human breast carcinoma MDAMB-231 cells
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INTRODUCTION
Breast cancer is often not considered as a single disease but a
family of diseases. Triple-negative breast cancer (TNBC), is a
specific subtype of epithelial breast tumors that are immuno-
histochemically negative for the protein expression of the
estrogen receptor (ER), the progesterone receptor (PR) and lack
over expression/gene amplification of HER2 (Kurose et al., 2001;
Hayes, 2010). There are many treatment options for the hormone
receptor “positive” tumors but fewer options exist for those that
don’t. In fact no specific molecular targets for this subgroup of
breast cancer patients are yet identified thus providing a major
arena for exploration. Various reports suggest that this class of
tumors are extremely aggressive in nature and have been found
to show distant metastasis (De Laurentiis et al., 2010; Hudis and
Gianni, 2011). To improve clinical prognosis of TNBC, we must
elucidate the signaling pathways operating and the modes of
development of TNBC and utilize this knowledge in improving
the present day therapy regimes. Therefore, development of
therapeutic strategies to target these TNBC cells may help to
overcome the drawbacks in TNBC treatment.
Calcium (Ca2+) controls different cellular processes like
short-term responses such as secretion and muscle contraction
as well as long-term regulation of cell proliferation and
differentiation (Berridge et al., 2000, 2003). Different mechanisms
are involved to maintain the difference in calcium concentration
from outer environment to cellular cytoplasm. Store-operated
Ca2+ entry (SOCE) is one of the major mechanism by
which cell maintains calcium homeostasis. In response to
depletion of Ca2+ from intracellular Ca2+ stores [primarily
the endoplasmic reticulum (ER)] cell activates specific plasma
membrane channels, termed as store operated channels (SOCs)
(Putney, 1986; Spassova et al., 2006). Stromal interacting
molecule 1 (STIM1) is an ER- residential highly conserved type-I
membrane, protein, containing a luminal EF-hand Ca2+-binding
domain. It plays a dual role as an ER calcium concentration
sensor and activator of SOCE (Liou et al., 2005; Spassova et al.,
2006). STIM1 senses the depletion of Ca2+ from the lumen
through its EF hand and initiates the process of store-operated
Ca2+ entry, where a pool of STIM1 translocates to the plasma
membrane to regulate SOCE, but the population of STIM1 that
activates SOCE remains in the ER and co-clusters with Orai1 in
ER-plasma membrane junctions (Putney, 1986; Liou et al., 2005;
Spassova et al., 2006).
Recently various studies implicate that STIM and Orai
proteins mediated SOCE is responsible in various processes
during oncogenic transformation, apoptosis, proliferation,
angiogenesis, metastasis and antitumor immunity. Ca2+
signaling mediated by SOCE is needed to induce genetic changes
in normal cells, which implicates malignancies in premalignant
cells. Several evidences indicate that STIM/ORAI-mediated
SOCE promotes uncontrolled growth and metastasis in different
types of cancer. McAndrew et al. (2011) showed from 295 breast
cancer microarray data, that patients with a STIM1-high profile
demonstrated abnormal SOCE and poorer prognosis. Orai1
and STIM1 expression were enhanced in therapy-resistant other
types of carcinoma cells also (Xie et al., 2015). Pharmacological
inhibition of STIM1- mediated SOCE can surprisingly enhance
chemotherapy mediated lung or pancreatic cancer regression
(Li W. et al., 2013; Kondratska et al., 2014). As a result, there
has been an urgent need to develop of SOCE inhibitors that can
be used to fight against cancer. Over the past decades, several
small-molecule SOCE inhibitors have been developed which
showed great promise in the chemotherapy. As SOCE implicates
in several cell responses such as cell growth, survival, and
apoptosis, it represent a primary target for treatment of TNBC
also.
In chemotherapy natural product-oriented synthetic
derivatives have played a significant role (Koehn and Carter,
2005; Mishra and Tiwari, 2011). The commonly used anti cancer
agents such as paclitaxel and actinomycin C were originally
developed from natural products. 3,3′-di-inolyl methane (DIM)
produced in the stomach from indole-3-carbinol (I3C) which
is the main ingredients of vegetables of the Brassica family. I3C
is converted via acid-catalyzed reactions in the stomach in its
most biologically active metabolite DIM (Bjeldanes et al., 1991).
DIM has been studied extensively as an anticancer agent due
to its ability to inhibit the growth of various type of cancer
cell types in vitro and in vivo (Nachshon-Kedmi et al., 2004)
and has showed promising results in clinical trials for the
treatment of prostate cancer (Heath et al., 2010). Nevertheless,
the development of DIM as a potent therapeutic agent is limited
by numerous factors which are mainly because of its easy
transformation into many polymeric products in vivo (Selvaraj
et al., 2015). These compounds have some general targets but
have some prominent biological effects on breast cancer cells and
significantly high concentrations are required to arrest cell cycle
progression in breast cancer cells (from 50 to 200 µM) (Safe
et al., 2008). As alternatives to DIM as a chemotherapeutic agent
for the treatment of breast cancer, several DIM analogs are now
being characterized showing higher anti-proliferative properties
(Dejeans et al., 2010; Li G. et al., 2013).
In the current study, we have reported the synthesis of a new
DIM derivative Phemindole [3,3′-(4-hydroxyphenylmethylene)-
bis-(7-methy-1H-indole)] and our experimental findings
revealed that it exhibited better anti-tumor effect when directed
against triple negative breast cancer (TNBC) cells than DIM
alone. In this study, we showed that Phemindole exhibited
in vitro potency that is two orders of magnitude higher than
that of DIM in suppressing the proliferation of TNBC tumor
cells. Furthermore, we have delineated the mechanistic role
of Phemindole in inducing apoptosis in TNBC cells in vitro
as well as tumor regression in ex ovo models respectively. It
has been acknowledged that 4T1 cells are a murine TNBC
cell line which serves as a suitable mouse model for the study
of TNBC (Pan et al., 2012); therefore we also developed the
4T1 murine mammary carcinoma model in BALB/c mice and
validated the effect of Phemindole in tumor regression in vivo.
Underlying molecular mechanisms revealed that Phemindole
showed regulation of cytochrome c via mitochondrial dependent
pathway in TNBC cells. Simultaneously, Phemindole was found
to regulate Store Operated Calcium Entry (SOCE) by down
regulating STIM1 protein in TNBC cells. STIM1 played an
important role in gene regulation by controlling the ER calcium
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homeostasis in breast cancer cells (Lax et al., 2006). Treatment
of the TNBC cells with Phemindole favored down-regulation
of the elevated STIM1 levels through retarded translocation
from ER to the plasma membrane ORAI channel ultimately
resulting in ER stress generation and apoptosis of TNBC cells.
Our study thus reveals for the first time an intricate mechanism
of how the Phemindole triggered death in highly aggressive
TNBC cells. These results indicate the translational potential of
Phemindole as a component of chemotherapeutic strategies for
TNBC treatment.
MATERIALS AND METHODS
Chemical Synthesis and
Characterization of Phemindole
On the basis of previous discovery on natural product analogs as
anti cancer agent we have designed the anti cancer compound of
3,3′-(4-hydroxyphenylmethylene)-bis-(7-methy-1H-indole). We
have been reviewing the Aryl methyl ring substituted analogs of
3,3′ di indolyl methane because there are many reports in the
literature displaying interesting anti-cancer activity of this class of
natural products, especially several symmetrical ring-substituted
DIMs and 1,1-bis(3′-indolyl)-1- (p-substituted phenyl)methanes
(methylene substituted DIMs), DIM and ring-substituted DIMs
recently shown activate the aryl hydrocarbon receptor (AhR)
in breast cancer cells and their activity in breast cancer may
be due, in part, to inhibitory AhR–ER crosstalk (Chen et al.,
1998; Safe et al., 2008; Hall et al., 2010). Thus, we synthesized
and evaluated the anti-cancer activity of Phemindole, which as
in yet has not been reported to have anti-cancer activity. The
structure of Phemindole is shown in Figure 1A. To synthesize
this compound, a mixture of 4-hydroxybenzaldehyde (1 mmol),
7-methyl indole (2mmol) and I2 (0.2mmol) were ground together
in a mortar with a pestle at room temperature for several minutes.
After completion of the reaction was monitored by TLC, the
mixture was treated with Na2S2O3 to yield solid product, which
was purified by column chromatography (EtOAc: hexane = 1:9)
to afford the pure product (290 mg, 79%). Physical and structural
characterization data obtained for Phemindole showed its purity
to be higher than 95%. Phemindole was dissolved in DMSO
to make a stock concentration at 20 mM for cell culture
experiments. The final DMSO in the cell culture medium was
0.1% (v/v), and the same amount of DMSO was used as a
negative control. The structure of Phemindole was confirmed by
IR analysis that revealed 3416, 2366, 2349, 2341, 1506, 1454, 1316,
1213, 1090, 794, 773, 584 cm−1. The purified compound also
yielded the 1H NMR spectra (500MHz, CDCl3): δ 7.75 (br s,2H),
7.21 (d, j = 8.0 Hz, 2 H), 7.17 (d, j = 8.5 Hz, 2 H), 6.95–6.89
(m, 4H), 6.70 (d, j = 8.0 Hz, 2 H), 6.61–6.59 (m, 2H), 5.78 (s, 1
H), 1.25 (s, 6 H, 2 CH3); ESI-MS: 389.1 [M + Na]+; Anal. Calcd.
For C25H22N2O (366.45): C, 81.94; H, 6.05%; found: C, 81.80; H,
6.15%.
Cell Culture, Reagents and Transfection
Normal Breast Epithelial cell line MCF-10A was kindly gifted
by Tamara Lah and Dr. Neža Podergajs, National Institute
of Biology, Ljubljana, Slovenia, MDAMB-231 cell line was
obtained from the National Centre For Cell Science (NCCS),
India. Cells were maintained and propagated in DMEM
with various supplements as suggested by NCCS and kept
at 37◦C with 95% humidified air and 5% CO2. Culture
medium was changed twice weekly and cells were maintained
in complete media, until reaching 90% confluence. cDNA
en-coding full-length human STIM1 (a generous gift from
Dr. Paul Worley John Hopkins University) was transfected
in to MDAMB-231 cells using Lipofectamine 2000 in Opti-
MEM medium as per supplier’s instructions and assayed after
24 h. Isolation of stably expressing clones were done by
limiting dilution and selection with G418 (500 mg/ml), and
the cells that survived were cloned and assessed for STIM1
expressions by Western blot analysis. MDAMB-231 cells were
transfected with 300 pmol of STIM1 siRNA (Santa Cruz
Biotechnology) and Lipofectamine 2000 (Invitrogen) separately
for 12 h. Levels of STIM1 proteins were estimated by Western
blotting.
Cell Viability Assays
For viability assays, cells were seeded on 96-well plates at a density
of 0.5 × 105 cells/well. Cell viability was measured by using
the MTT cell proliferation assay kit (HIMedia). Absorbance was
read at 570 nm (630 nm as a reference) on a microplate reader
(Molecular Devices). Cell viability was expressed as a percentage
of the control culture.
Determination of Cell Cycle by Flow
Cytometry
Briefly cells were plated at a density of 1 × 106 cells/ml in each
Petri dish in DMEM for 16–20 h. Thereafter the cells were treated
with Phemindole at 10 µm for 24 h. At the end of treatment the
cells were collected and fixed with 100% methanol for 5 min at
−20◦C. After centrifugation, the cell pellets were collected with
4 µg/ml of propidium iodide solution containing 100 µg/ml
of RNase and 1% Triton X-100 for 30 min. Subsequently, the
samples were analyzed in a FACS calibur system (BD Biosciences)
using CellQuest software. The percentage of cell cycle phases was
analyzed by ModFit LT software (version 2.0, BD Biosciences).
Histogram display of DNA content (x axis, PI fluorescence)
versus counts (y axis) has been displayed. CellQuest statistics was
employed to quantitate the data at different phases of cell cycle.
Determination of Cellular Apoptosis by
AnnexinV
For the determination of cell death, cells were stained with
propidium iodide and annexin V-FITC (BD Pharmingen) and
analyzed on a flow cytometer (FACS Calibur, BD Bioscience)
equipped with 488 nm argon laser light source, using Cell
Quest Software (BD Biosciences). Electronic compensation of
the instrument was done to exclude overlapping of the emission
spectra. Ten thousands total events were acquired for analysis
using Cell Quest software. Annexin V/FITC positive cells were
regarded as apoptotic cells.
Frontiers in Pharmacology | www.frontiersin.org 3 May 2016 | Volume 7 | Article 114
fphar-07-00114 May 2, 2016 Time: 18:21 # 4
Chakraborty et al. Anti-Tumor Activity of Phemindole
FIGURE 1 | Effects of di-indolyl methane analog, Phemindole on cell viability and apoptosis in human triple negative breast cancer cells. (A) The
chemical structure of di-indolyl methane and its analog, Phemindole. (B) The effect of Phemindole on cell viability in human breast cancer cells, MDAMB-231 and
normal breast epithelia, MCF-10A. Cells were treated with Phemindole and DIM at different concentrations for 24 h as indicated cell viability was determined by MTT
assay, IC50 values were indicated for each treatment. (C) Phase contrast images showing the effect of Phemindole (10 µM) on MDAMB-231 cells. Arrows in the
treated sets are indicating apoptotic cells. (D) SEM micrographs of MDAMB-231 cells showing cellular membrane blabbing due to apoptosis in Phemindole treated
set (indicated by arrows) (right). Untreated control cell showed normal morphology (left) (E) Representative images for cell apoptosis stained with Annexin V-FITC/PI.
Cells were treated with Phemindole at 10 µM concentration for 24 h, followed by staining with Annexin V-FITC/PI and analyzed by flow cytometry as described in
methods. Values are mean ± SE from three independent experiments. *p < 0.05, **p < 0.01; all versus control group.
Detection of Mitochondrial Membrane
Potential and Intracellular Reactive
Oxygen Species (ROS) Generation
The changes in mitochondrial membrane potential were
determined using JC1 (Molecular probes). Cells were treated
with DMSO or Phemindole for indicated time periods, harvested,
washed twice in PBS, resuspended in PBS supplemented
with JC1 (20 nM), incubated at 37◦C for 15 min in
the dark, and immediately analyzed by flow cytometry or
fluorescence microscope. The intracellular accumulation of
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ROS was examined by flow cytometry after being stained
with the fluorescent probe, DCFH-DA (2,7-dichlorodihydro-
fluorescein di acetate; Molecular probes) (10 µM). DCFH-
DA was deacetylated in cells by esterase to a non-fluorescent
compound, DCFH, which remains trapped within the cell
and is cleaved and oxidized by ROS in the presence of
endogenous peroxidase to a highly fluorescent compound, DCF
(2,7-dichlorofluorescein). Briefly, MDAMB-231 cells were seeded
in 6-well plates (5 × 105 cells/ml), treated with or without MPB
and other compounds for different time periods, and incubated
with 10µM DCFH-DA for 30 min at 37◦C. Cells were washed, re-
suspended in PBS, and ROS levels were determined using FACS
Calibur flowcytometry.
Immunoprecipitation and Western
Blotting
MDAMB-231 and MDAMB-468 cells were lysed in buffer
(10 mm Hepes, pH 7.9, 1.5 mm MgCl2, 10 mm KCl, and
0.5 mm DTT) and nuclei were pelleted by a brief centrifugation.
The supernatant was spun at 100,000 × g to get a cytosolic
fraction. The nuclear extract was prepared in buffer containing
20 mm Hepes, pH 7.9, 25% (v/v) glycerol, 420 mm KCl,
1.5 mm MgCl2, 0.2 mm EDTA, 0.5 mm DTT, and 0.5 mm
PMSF. All buffers were supplemented with protease and
phosphatase inhibitor mixtures. For direct Western blot analysis,
cell lysates of the particular fractions containing 30 µg of protein
were separated by SDS-polyacrylamide gel electrophoresis and
transferred to PVDF membrane. The protein levels were
determined with specific antibodies (Santa Cruz Biotechnology).
For immunoprecipitation studies STIM1 and Orai1 immune
complexes were immunoprecipitated using Orai1 antibody with
Protein A-Sepharose beads (Sigma). The immunopurified were
immunoblotted with STIM1 antibody. The protein of interest
was visualized by chemiluminescence. Equal protein loading
was confirmed by reprobing the blots with β-actin/histone
H1/GAPDH antibody (Santa Cruz Biotechnology).
Calcium Measurements
Cytosolic calcium concentration was measured using
a fluorimetric ratio technique. Cells were subjected to
centrifugation and then re-suspended in phosphate-buffered
saline (PBS) supplemented with 1 mg/ml of bovine serum
albumin and incubated with Fura-2AM (final concentration
5 µM) (Sigma) in the absence of light for 30 min at room
temperature. This was followed by centrifugation and cells
were then re-suspended in calcium-free Hanks’ buffered saline
solution (135 mm NaCl, 5.9 mm KCl, 1.2 mm MgCl2, 11.6 mm
Hepes, 11.5 mm glucose adjusted to pH 7.3 with NaOH) prior to
measurements. After centrifugation cells were again suspended
in 3 ml of Hanks’ buffered saline solution in a quartz cuvette
and analyzed in a Hitachi spectrofluorimeter equipped with a
stirring apparatus and a thermostatted (37◦C) cuvette holder,
connected to a computer. The fluorescence was recorded at
510 nm using an excitation source of 340 or 380 nm. Maximum
Fura-2 fluorescence (Fmax) was observed on addition of 1 µm
ionomycin (Sigma) to the cell suspension along with 10 mm
CaCl2, and minimum fluorescence (Fmin) was determined
without added calcium in the presence of 5 mm EGTA (Sigma).
The cytosolic [Ca2+] was calculated from the Fura-2AM
fluorescence intensity as: [Ca2+]cyt = Kd (F - Fmin)/(Fmax - F),
where Kd = 229 nm for Fura-2 and R is the ratio of fluorescence
values (F) (R= F340/F380).
Time Lapse calcium kinetics measurement using Fluo-3AM
was performed in Leica Confocal microscope. Fluo3-AM loaded
cells were imaged using a Leica Confocal system attached to a
Leica inverted microscope. The Fluo3-AM indicator was excited
by the 506 nm. The emitted fluorescence was measured at
wavelengths of ∼526 nm. Fluorescence signals were captured
(1024 pixels × 1024 pixels) in real time. Time series Confocal
optical sections were collected in the image-scan x-y-t mode.
Planar images were recorded at specific time intervals (15 s).
Background signals from auto fluorescence were adjusted to a low
level by using unstained cells before image acquisitions.
Scanning Electron Microscopic (SEM)
Study
The morphology of breast carcinoma cells under different
conditions were observed under scanning electron microscope
(SEM). By following the protocol of Bhattacharya et al. (2015)
the cells were grown on poly-L-Lysine (1:10) coated glass slide
(1 cm × 1 cm) overnight at 37◦C in 5% CO2. Next day,
cells were treated with specific dose of Phemindole and kept
in the CO2 incubator for overnight. Next day, the cells were
washed by sodium cacodylate buffer, and then fixed with 2.5%
glutaraldehyde buffered in sodium cacodylate for 1 h. The
samples were washed with sodium cacodylate buffer thrice, and
dehydrated through a series of alcohol concentrations (10, 30,
50, 70, 90, and 100%), and subjected to air drying. The samples
were then visualized by EVO-18 special edition SEM (ZEISS,
Germany).
Transwell Migration Assay
Migration assay was done using cell culture inserts (BD
Biosciences, Sparks, MD, USA). Cell culture inserts with pores
(8 µm) were placed in the 12-well companion plate containing
100 ml of DMEM Media without chemo-attractant, i.e., serum.
In the upper half of the insert 2 × 105 cells was placed inside
the chamber. The serum containing DMEM (10% FBS) was
then added to the lower chamber of the 12-well plate. Next day
the cells in the insert were washed with PBS, fixed with 3.7%
formaldehyde and were permeabilized using methanol. At last,
cells were stained with Giemsa stain for 30 min. Cells present in
the lower part of the inserts were determined by counting cells in
three microscopic fields per well, and the extent of migration will
be expressed as an average number of cells per microscopic field.
Wound Healing Assay
The migration of breast cancer cells under different conditions
were determined by bidirectional wound healing assay. Firstly
the MDAMB-231 cells were grown to 90% confluency in 12
well plates after which a scratch was done using sterile pipette
tip to form a bidirectional wound. Migration was quantitated
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by a semi-automated, computer-assisted procedure by a person
blinded with respect to the experimental treatment. The data
from triplicate wells were calculated as the means ± SEM, the
migration rate of control cells were taken as 100% and healing
rate of other plates were compared with respect to control cells.
Fluorescence Imaging
For fluorescence imaging, the cells were fixed with 3.7%
formaldehyde and permeabilized with 0.1% Triton X-100. Cells
were then either incubated with anti STIM1, ORAI1 antibody,
anti cytochrome C, p-FAK antibody followed by FITC/TRITC-
conjugated secondary antibody (Sigma). The nucleus was stained
with DAPI (SRL). The samples were mounted on clean glass slides
using Vector Shield mounting Media and visualized under the
fluorescence microscopes (Leica). Images were quantified using
this formula to calculate the corrected total cell fluorescence
(CTCF). CTCF = Integrated Density – (Area of selected cell X
Mean fluorescence of background readings).
Ethics Statement
The study was performed under strict accordance with the
protocols of the National Institute of Health guidelines for the
Care and Use of Laboratory Animals (NIH publication No. 85
−23 revised 1985: US Department of Health, Education and
Welfare, Bethesda, MD, USA). The experimental outline also
met the National Guidelines on the Proper Care and Use of
Animals in Laboratory Research (Indian Science Academy, New
Delhi, India) and the protocol was approved by the Institutional
Animal Ethics Committee (IAEC) of Bose Institute, Kolkata,
India (Approval No. IAEC/BI/08/2012). The animal breeding and
experimental facility are registered with the Committee for the
Purpose of Control and Supervision of Experiments on Animals
(CPCSEA), Ministry of Environment and Forest and Climate
Change, Government of India. Euthanasia was performed by
decapitation under sodium pentobarbital anesthesia, and the
efforts were made to minimize the pain and sufferings to the
animals.
Tumor Regression in Ex Ovo Model
The semi-quantitative Chorioallantoic Membrane (CAM) assay
was performed as described (Zijlstra et al., 2002) with a few
modifications to detect the presence of human cancer cells.
Briefly, 2 × 106 MDAMB-231 cells were inoculated on the
CAM of 6-day old chicken embryos. A tumor was observed
within 2 days. On day 10 and 12, chicken embryos were
treated intravenously with Phemindole at a dosage of 10 µm/ml.
Untreated embryos served as control. On day 15, the embryos
were sacrificed. To detect human cells in the chick tissues,
primers specific for the human alu sequences were used to
amplify the human alu repeats present in genomic DNA against
chick GAPDH as loading control.
4T1 Induced Tumor Regression Study in
BALB/C Model
Sixteen female BALB/c mice (8 weeks old and weighing ∼20 g)
purchased from Chittaranjan National cancer research institute
and housed in the animal house of Bose Institute and were
maintained according to the guidelines of the Institutional
Animal Ethical Committee (CPCSEA). After acclimatization
under the laboratory condition, they were randomly divided
into four groups, each group having four mice (N 1/4 4) (i)
Untreated control group. (ii) untreated 4T1tumor bearing set
(which were injected with 4T1 cells in mammary fat pads), (iii)
10 mg/Kg bodyweight Phemindole treated tumor bearing set (iv)
15 mg/Kg bodyweight Phemindole treated tumor bearing set.
The Phemindole dissolved or suspended in 0.1 mL PBS were
injected subcutaneously on the inside of either mammary fat
pads every 48 h with a 25 gage syringe. Each mouse received
7 doses of its designated drug over a 14 days period. Mice in
the untreated group were similarly given 7 doses of 0.1 mL of
PBS. Tumor volume was measured on every date of treatment
and tumor weight was evaluated following sacrifice of the mice.
Blood was collected from the retro-orbital plexus of anesthetized
mice of each group by rupturing it with a fine capillary and
was kept at 4◦C for 1 h in slant position. It was centrifuged
at 2000 rpm for 10 min at 4◦C. Clear serum formed above
the clot was collected. Serum specific Liver and Kidney toxicity
markers were measured using commercially available standard
kits purchased from Himedia, India following manufacturer’s
protocol. For histological studies, the liver, kidney, spleen, tissues
collected from all the groups were fixed with 10% phosphate
buffered neutral formalin. Following dehydration in graded (50–
100%) alcohol, the tissues were embedded in paraffin. Thin
tissues sections, having 4–5 µM thickness, were cut and stained
with routine haematoxylin and eosin (H&E) stain for photo
microscopic assessment.
Statistics
Values are shown as SE except where otherwise indicated.
Data were analyzed, and when appropriate, significance of the
differences between mean values was determined by Student’s
t-test, one way ANOVA, Results were considered significant at
p< 0.05.
RESULTS
Phemindole Reduced Cell Viability and
Induced Cell Apoptosis in Human Triple
Negative Breast Cancer Cells
In order to assess the effect of Phemindole (Figure 1A) on TNBC
cells MTT assay was performed. Interestingly our observations
revealed significant death of the MDAMB-231 with increasing
concentrations of Phemindole and the percentage of cell death
was substantially higher at even lower doses in comparison to
that of 3,3′di Indolyl methane (DIM) (Figure 1B). Results of this
figure clearly revealed that Phemindole induced nearly 50% cell
death as compared to only 20% with DIM at a dose of 10 µM
on treatment for 24 h. In contrast the percentage of normal
breast epithelial MCF-10A cell survival as assessed by MTT
assay was significantly higher when subjected to Phemindole
treatment (Figure 1B). These findings thereby established the
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fact that the synthesized indole derivative Phemindole showed
prominent cytotoxicity in TNBC cells at a dose in which it
left the normal breast epithelial cells (MCF-10A) unaffected.
Additionally, our findings also highlighted that Phemindole
creates potent toxicity in TNBC cells (MDAMB-231) more
efficiently at a much lower doses than DIM alone. To further
reinstate the findings obtained from MTT assay, we performed
phase contrast microscopic imaging of MDAMB-231 cells on
treatment with 10 µM dose of Phemindole. Interestingly our
observations revealed that Phemindole produced significant
level of morphological change to induce death in TNBC cells
(Figure 1C). It has been acknowledged that in addition to loss
of membrane integrity, apoptotic cells can also be distinguished
based on morphological hallmark such as membrane blebbing
and apoptotic body formation (Azimi et al., 2014). Thus we
also monitored the changes in cellular morphology, using
SEM and our observations revealed the formation of apoptotic
body and membrane blebbing, a prominent indication of cell
apoptosis which is quite evident from the SEM micrograph
as shown in Figure 1D. To further determine whether the
increase in percentage of cell death was due to apoptosis or
not we used flowcytometry to analyze the number of Annexin-
V-positive cells. Results illustrated in Figure 1E showed a
significant amount of increase in the number of Annexin-V-
positive MDAMB-231 cells, indicating apoptosis as the primary
cause of Phemindole mediated cell death. These result thereby
indicated that Phemindole significantly induced apoptosis in
MDAMB-231 cells at a dose 10 µM.
Phemindole Induced Apoptosis via ROS
Generation through Mitochondria
Mediated Pathway
To further explore the anti-tumor activity of the Phemindole, we
were interested in studying the detailed molecular mechanism
of induction of apoptosis in TNBC cells. Immuno-fluorescence
images of cells stained with JC-1 indicated a drop in
the mitochondrial membrane potential more significantly in
MDAMB-231 cells treated with Phemindole (Figure 2A, left
panel). Figure 2A (right panel) summarizes our finding that
the fluorescence intensity ratio of red to green declined
dramatically in Phemindole treated cells clearly indicating a loss
in the mitochondrial membrane potential of the TNBC cells.
Additionally, we checked for Cyt C expression which is deemed
to be one of the most significant factors in the mitochondria
mediated apoptosis cascade. Western blotting analysis revealed
an increased expression of Cyt C in the cytosol (Figure 2B)
which was further validated from our Immunofluorescence
imaging data. In untreated cells, Cytochrome c-FITC had a very
weak plaque like signal, while an intense signal was evident
in the cytoplasm of the Phemindole treated MDAMB-231 cells
(Figure 2C). This undoubtedly proved the fact that Phemindole
treatment facilitated the cytosolic diffusion of Cyt C from
the mitochondria which subsequently initiated the cleavage of
Caspase 8, Caspase-9, Caspase-3 and finally PARP cleavage
(Figure 3A) to induce apoptosis in the MDAMB-231 cells.
It is well established and also supported by many scientific
reports that high levels of ROS formation usually initiate the
mitochondrial membrane potential disruption of many types of
cells (Stowe and Camara, 2009). In the present experimental set
up, we first determined whether treatment Phemindole could
up-regulate the formation of ROS in MDAMB-231 cells. Cells
were treated with different concentrations (1, 5, 10, and 15 µM)
of Phemindole, and the ROS generation was measured using
the fluorescent dye DCFH-DA and the results were analyzed
using flow cytometry. Treatment with 5 µM of Phemindole
induced significant high levels of ROS production in MDAMB-
231 cells (Figure 3B). To further analyze the situation and to
justify the role of ROS in the apoptotic cascade, the MDAMB-231
cells were pre-treated with 5 mM concentration of NAC (N-
acetyl Cysteine), a very potent and widely accepted antioxidant.
Interestingly, our findings highlighted that treatment with NAC
resulted in a sustained decrease in ROS generation which
is quite close to normal. Moreover, when these NAC pre-
treated cells were subjected to treatment with Phemindole, their
ROS generation was prominently declined in comparison to
Phemindole treatment alone (Figure 3C). Therefore, from the
above observation it may be concluded that Phemindole failed
to initiate ROS generation in NAC pre-treated cells and thus the
percentage of apoptotic cell death was also subsequently declined
(Figure 3D). Interestingly, results of Figure 3D clearly revealed
that NAC pretreated followed by Phemindole treated cells
showed reduction in percentage of cell apoptosis to nearly 25%,
whereas only Phemindole treatment alone showed about 60% of
cell apoptosis thereby suggesting the probable involvement of any
other signaling cascade in addition to the mitochondria mediated
ROS generation pathway. Thus we were further prompted to
extend our studies to delineate the involvement of other cellular
pathway which may be coupled with the ROS generation pathway
by Phemindole to induce substantial apoptosis in TNBC cells.
STIM1 Was Down Regulated in
Phemindole Treated MDAMB-231 Cells
After elucidating the role of Phemindole in inducing cell death
via ROS generation in a mitochondrial-dependent pathway, we
again raised the question about the involvement of some other
pathway which may be coupled with the ROS generation in
inducing substantial death in MDAMB-231 cells. It is well known
that store-operated Ca2+ entry (SOCE) is crucial for maintaining
intra cellular calcium homeostasis and functions (Selvaraj et al.,
2015). Stromal interaction molecule 1 (STIM1), acts as a key
component of SOCE, by controlling a dual mechanism as an
ER Ca2+ receptor and an SOCE exciter. Differential expression
of STIM1 has been discovered in several human cancer cells
(Azimi et al., 2014; Sun et al., 2015; Wen et al., 2016).
Keeping this in mind, we were interested to evaluate the role
of Phemindole on SOCE in MDAMB-231 cells. To investigate
whether Phemindole has any effect on the expression of STIM1
in MDAMB-231 cells, we performed the immuno-fluorescence
staining and western blot of STIM1. On immuno-staining
(IF), we observed that, MDAMB-231 cells showed a reduction
in fluorescence of STIM1 on treatment with Phemindole
(Figure 4A). Western blotting results also reinstated our findings
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FIGURE 2 | Phemindole potentiates mitochondrial membrane potential depolarization and Cytochrome C release in MDAMB-231 cells.
(A) Fluorescence microscopic images of the MDAMB-231 cells stained with JC-1 dye for detecting the changes in mitochondrial membrane potential in both control
and Phemindole treated cells. The red fluorescence intensity in the Phemindole treated cells was weaker than in the control cells (Left panel). Bar diagram shows the
quantitative monomer (Red Fluoroscence)/dimer (green fluorescence) ratio at different time point of Phemindole (10 µM) treated set (Right panel). (B) Western blot
assay showing Cyt C release (upper panel). The level of Cyt C increased in the cytoplasm and decreased in the mitochondria of the MDAMB-231 cells treated with
the Phemindole, indicating that Phemindole caused the release of Cyt C from mitochondria. β-actin for cytosol and Mn-SOD for mitochondria were taken as positive
control. Blots are representative of three independent experiments and quantifications are indicated by Bar diagram (lower panel). Values were normalized by
intensity of positive control. (C) Immunofluorescence images of Cyt C –TRITC (Red) and DAPI (blue) staining in MDAMB-231 cells from untreated and Phemindole
treated sets (Left panel). Pictures showed representative cells of each population and were representative of three independent experiments. Corrected cytoplasmic
red Fluorescence intensity was quantified following the protocol described in material method section (Right panel). ∗, ∗∗, ∗∗∗ indicate p < 0.05, p < 0.01,
p < 0.0005 versus untreated cells.
obtained from our immuno-fluorescence data (Figure 4B, upper
panel). Simultaneously we also checked the expression of Orai1 in
control and Phemindole-treated MDAMB-231 cells. Importantly,
Phemindole treatment produced no alteration in the total
or surface expression of Orai1 (Figure 4B, middle panel).
However, a decrease in total STIM1 levels in a time-dependent
manner was observed in the Phemindole treated TNBC cells
(Figure 4B, lower panel). Previous reports suggest that upon
store-depletion, STIM1 is transported to the ER–PM junctions
where it coordinates with Orai1 channels (Carrasco and Meyer,
2011). Thus, co-immunoprecipitation experiments using STIM1
antibodies were carried out under control and store-depleted
conditions. Addition of the commercially available SERCA
pump inhibitor, thapsigargin (Tg), resulted in an enhancement
in STIM1–Orai1 interaction in MDAMB-231 cells, which was
declined on Phemindole treatment (Figure 4C). These data
henceforth suggested that Phemindole could inhibit STIM1–
Orai1 functional interaction that resulted in inhibition of Ca2+
entry and induced cell death in TNBC cells. The findings was also
re-evaluated by double immuno-staining of MDAMB-231 cells
in following three condition untreated, Tg treated, Phemindole
treated (Figure 4D).
Store Operated Calcium Entry Was Also
Suppressed in Phemindole Treated
MDAMB-231 Cells
Stromal interaction molecule1 activated Orai1 by interacting
with it at plasma membrane, and this interaction was crucial
for SOC-mediated Ca2+ entry (Selvaraj et al., 2015). Keeping
this thought in mind we next investigated whether SOCE is
altered upon Phemindole treatment as Phemindole was already
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FIGURE 3 | Reactive oxygen species (ROS) production with Caspase activation is one of the reason of Phemindole mediated MDAMB-231 cells
apoptosis. (A) Western blot analysis of cleaved caspase-3, cleaved caspase-9, cleaved caspase-8 and cleaved-PARP in control and Phemindole treated
MDAMB-231 cells (Left panel). β-actin was used as loading control. Blots are representative of three independent experiments and quantifications are indicated by
Bar diagram (Right panel). Values were normalized by intensity of positive control. (B) Line diagram representation of the dose dependent ROS production in
MDAMB-231 cells on treatment with Phemindole. (C) Phemindole treated MDAMB-231 cells were assessed by flow cytometry for ROS generation by measuring the
DCF-fluorescence intensity and the data was represented by histogram overlay. (D) Percentage of cell death from Phemindole induced with/without NAC (a
pharmacological inhibitor of ROS) was assessed and represented in bar diagram. As described in methods the statistic data were presented as mean ± SE from
three independent experiments. ∗,∗∗,∗∗∗,# indicate p < 0.05, p < 0.01, p < 0.0005, p < 0.05 respectively versus untreated or control group.
found to down regulate STIM1 expression. To evaluate SOC-
mediated Ca2+ entry, we treated the cells with thapsigargin
(Tg, 1 µM) to bring about depletion of the ER Ca2+ stores.
Our observation revealed that in the absence of extracellular
Ca2+ the increase in [Ca2+]i evoked by Tg (first peak) was
prominently declined on Phemindole treatment (Figure 5A,
Left panel). Simultaneously, even upon addition of external
Ca2+(1 mM), which initiated the SOC-mediated Ca2+ entry,
the [Ca2+]i was also declined (second peak) in Phemindole
treated MDAMB-231 cells (Figure 5A, right panel). To address
the question that whether Phemindole treatment can also
alter the constitutive calcium influx in MDAMB-231 cells
we repeated the previous experimental condition except the
thapsigargin stimulation. Figure 5B showed that there was no
significant difference in calcium influx ratio between normal
and Phemindole treated MDAMB-231 cells. Additionally our
Fluorimetric data was revalidated using time Lapse calcium
kinetics measurements and changes in the calcium influx in
control and Phemindole treated sets have been illustrated in
Figure 5C. These results indicated that SOCE was inhibited on
treatment with Phemindole, which could be an important factor
to restrict cell proliferation.
Phemindole Treatment Induced ER
Stress
Our previous results have shown that Phemindole disrupted
cellular calcium homeostasis by diminishing SOC mediated ER
calcium entry in the cells. These findings further encouraged us
to investigate whether this loss in ER–Ca2 provoked the unfolded
protein response (UPR) (Bravo et al., 2013; Selvaraj et al.,
2015). Our findings interestingly revealed that the UPR markers
(GRP78 and CHOP) were elevated significantly at the protein
levels (Figure 5D) on Phemindole treatment. Because ER stress
mediated CHOP activation has been known to be one of the
main causes of pro apoptotic protein Bcl2 down regulation (Tabas
and Ron, 2011), we next evaluated the changes of expression of
these proteins by western blot and immunostaining and as shown
in Figure 5E Phemindole treatment altered Bax, Bcl2 ratio by
decreasing the expression of Bcl2.
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FIGURE 4 | Phemindole downregulates STIM1 Expression. (A) Immunofluorescence images showing decreased expression of STIM1 in the MDAMB-231 cells
in response to Phemindole treatment. Anti STIM1 antibody was FITC tagged (green) and nuclei were stained with DAPI (blue) (left panel). Corrected Fluoroscence
intensity of STIM1 protein was quantified and represented as bar diagram (Right panel). Pictures showed representative cells of each population and were
representative of three independent experiments. (B) Western blot analysis depicting the changes in the expression pattern of STIM1 and Orai1. MDAMB-231 cells
were treated with Phemindole and Western blotted with respective antibodies as labeled in the figure (upper-left panel). Quantification of WB were depicted as bar
diagram (upper-right panel). MDAMB-231 cells were treated with 10 µM Phemindole for 24 h. Lysates were subjected to SDS–PAGE followed by Western blotting
(Continued)
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FIGURE 4 | Continued
with anti-Orai1 antibodies. β–actin was used as a loading control (middle-left panel). Band intensity was quantified and represented as a bar histogram
(middle-right panel). Cells were treated with 10 µM Phemindole and were harvested at 0, 6, 12, or 24 h after Phemindole treatment. Western blotting was done.
Antibodies used are labeled and β-actin was used as loading control (lower-left panel). Lower-right panel represent the normalized intensity of the bands. Blots
are representative of three independent experiments and quantifications are indicated by Bar diagram. Values were normalized by intensity of loading control.
(C) MDAMB-231 cells were treated with Phemindole or Tg under different conditions, lysed and proteins were subjected to immune precipitation by anti STIM1
antibody and followed by Western blotting with respective antibody (upper panel). (D) Representative Fluorescence images showed the association between
STIM1 (red) and ORAI1 (green) at plasma membrane. Nuclei were stained with DAPI (blue). Enlargements of the areas indicated by the color rectangles showed
overlap formation of STIM1 and Orai1 in plasma membrane due to Tg treatment (Left-middle) which is invisible in Phemindole treated set (left-lower) and not
prominent in un-stimulated control set (left-upper panel). Pictures showed representative cells of each population and were representative of three independent
experiments. Right panel, the Pearson’s and Manders coefficients determining the level of overlap of RITC and FITC on treatment with Control, thapsigargin (TG)
and Phemindole has been represented graphically. ∗,∗∗,∗∗∗,# indicate p < 0.05, p < 0.01, p < 0.0005, p > 0.05 respectively versus untreated or control group.
Decreased Ca2+ Entry in MDAMB-231
Cells Induced Cell Death and Restoration
of STIM1 Expression Reverted Back the
Phemindole-Mediated Restriction of Cell
Proliferation and Survival of TNBC Cells
To clearly interpret the link between Ca2+ influx and cell
survival, we next aimed to inhibit SOCE. Thus we added
SKF96365 in order to block SOC mediated Ca2+ entry (Chen
et al., 2013), and this resulted in significant decline in Tg induced
Ca2+ entry in MDAMB-231 cells. Also inhibition of SOCE by
using STIM1 siRNA gave the same result as in the previous
case (Figures 6A,B). Similarly, as expected cell proliferation
was also declined under both these above-mentioned condition
(Figure 6C). To further confirm the role of Phemindole in
mediating loss in Ca2+ influx (due to loss of STIM1 expression)
for death in TNBC cells, we over-expressed STIM1 protein in
MDAMB-231 cells. Over expressed MDAMB-231 cells showed
enhanced expression of STIM1 on treatment with Phemindole in
comparison to the untreated cells (Figure 6D). However, no rise
in control β-actin levels was observed. Importantly, Phemindole-
dependent inhibition of SOCE was also reverted back in cells with
STIM1 over-expression. Simultaneously, Bcl2 expression were
also restored in these treated cells (Figures 6D,E). In fact, both
cell survival and cell proliferation were reinstated in the cells that
over expressed STIM1 with Phemindole treatment (Figure 6F).
Cumulatively, these results suggested that elevation in STIM1
expression restored Phemindole-dependent loss in Ca2+ entry
and inhibited Phemindole-mediated cell death in TNBC cells.
In Vitro Effect of Phemindole on Cell
Cycle Distribution and Retardation of
TNBC Cell Migration
It is well known that MDAMB-231 cells are highly metastatic in
nature (Tu et al., 2011), as shown above molecular mechanism
through which Phemindole induced apoptosis in these cells,
we were further motivated to study whether Phemindole have
any anti mitogenic property or not. To determine the anti-
mitogenic effect of Phemindole, cell-cycle analysis was performed
in MDAMB-231 cells. Cells were accumulated in the G2/M
phase by Phemindole in a dose-dependent manner as shown in
Figure 7A. Five µM Phemindole produced the most eminent
effect on cell cycle arrest and about 50% cells were stalled in
G2/M phase. We further examined the effects of Phemindole on
cell cycle arrest-related proteins by immunoblot analysis Cyclin
A1, CDK inhibitor p21 are the main key players in the G2/M
checkpoint (Barboule et al., 1999; Li G. et al., 2013). Figure 7B
revealed that Phemindole treatment declined the protein level
of, Cyclin A1, CDK2 (Figure 7C) and increased the level of p21
(Figure 7D) in a dose-dependent manner thereby highlighting
the anti-mitogenic effect of Phemindole on TNBC cells. With
the objective of investigating the anti-migratory property of
Phemindole on breast carcinoma cells, we first elucidated the
different doses of Phemindole in inhibiting breast cancer cell
migration using in vitro bidirectional wound healing assay. As
illustrated in Figure 8A, Phemindole significantly (p < 0.001)
inhibited migration of MDAMB-231 cells even at a minimal
dose of 5 µM. These findings therefore highlighted the fact
that the synthesized Phemindole could prevent the in vitro
motility of breast cancer cells at significantly lower dose of
5 µM, which is much lower than the effective apoptotic dose,
i.e., 10 µM. To further confirm our above-mentioned findings
the transwell migration assay was performed using MDAMB-
231 cells. The cell line was treated with different doses of
Phemindole (1, 2.5, 5 µM) in a separate set. Interestingly, as
illustrated in Figure 8B, lesser number of cells were found
to have been migrated to the under surface of the transwell
insert when treated with 2.5 and 5 µM Phemindole in
comparison to a significant high number of migratory cells
in the case of control and 1 µM treated sets. Thus, we were
impelled to delineate specifically the effect of Phemindole on
retardation of in vitro breast cancer cell migration. Further
to determine the molecular mechanism playing behind this
finding, the status of phosphorylated Focal adhesion kinase
(FAK) in the treated or untreated cells was examined. FAK
is a 125-kDa non-receptor protein tyrosine kinase identified
in early 1990s as a protein associated with focal adhesions
(Luo and Guan, 2010). In most of the breast cancers, the
elevated levels of FAK (Focal Adhesion Kinase) expression
were already reported (Mitra et al., 2005). Subsequent analysis
using western blot and immune-cytochemistry showed that
pFAK expression has been decreased significantly in Phemindole
treated cells as compared to control cells (Figures 8C,D). These
observations discussed so far clearly reinstate our findings that
Phemindole display a potent anti mitotic and anti-migratory
property along with its significant anti-apoptotic nature in TNBC
cells.
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FIGURE 5 | Continued
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FIGURE 5 | Continued
The treatment of TNBC cancer cells with Phemindole reduces SOCE and induces ER stress. (A) Ca2+ measurement was performed in control and in the
presence of Phemindole (10 µM) in MDAMB-231 cells. Analog plots of the fluorescence ratio (340/380) from an average of 40–60K cells are shown (Left panel), Bar
diagram showed the qualitative values of fluorescence ratio (340/380) during calcium efflux and SOCE after TG treatment (Right panel). The statistic data were
presented as mean ± SE from three independent experiments. ∗p < 0.05, versus control group. (B) Non-stimulated Ca2+ influx of control and Phemindole treated
sets were assessed and fluorescence ratio were presented as a bar diagram. Data shown as average ± SE (n = 3). (C) Time Lapse calcium kinetics images
depicting the changes in calcium influx in control and Phemindole treated MDAMB-231 cells. (D) Western blot was performed to show the expression of unfolded
protein response (UPR) related protein (GRP78, IRE1α, and CHOP) in the TNBC cancer cells after 10 µM Phemindole treatment for 24 h. (E) Western blot analysis
determining the changes in Bax and Bcl-2 expression levels in MDAMB-231 cells. β-actin was used as internal loading control. Blots are representative of three
independent experiments and quantifications are indicated by Bar diagram (lower panel). Values were normalized by intensity of loading control. ∗,∗∗,∗∗∗,# indicate
p < 0.05, p < 0.01, p < 0.0005, p > 0.05 respectively versus untreated or control group.
In Vivo Validation of Tumor Suppressive
Effect of Phemindole in BALB/c Model
Furthermore, to determine whether treatment of Phemindole
inhibits the growth of solid tumor mammary cancer cells
in vivo, female BALB/c mice were used in which 4T1 mammary
carcinoma cells were injected into the mammary fat pads. The
injected 4T1 cells typically formed a solid tumor in the mammary
fat pad, which became visible 1 week following the injection
as shown in Figure 9A, and the volume of tumors increased
till the day of sacrifice. Starting 1 week after the injection of
4T1 cells until sacrifice, the mice were injected with Phemindole
(10 and 15 mg/kg body weight) i.p every alternate day for
next 14 days. The overall size of the tumor in the mammary
fat pad region showed a proportional morphological difference
in Phemindole treated mice as compared to the untreated
one (Figure 9A). Phemindole administration at 10 mg/kg
significantly suppressed tumor growth. At the end of the
experiment, tumor weight was found to be significantly lower
in the mice treated with 15 mg/kg of Phemindole as compared
to control subject (Figure 9B). Moreover, the administration
of Phemindole significantly reduced the volume of tumor as
compared to the control (Figure 9C). Furthermore, we were also
interested in exploring and validating the mechanism of action
of Phemindole in the in vivo model. It was observed that there
was a significant decrease in the expression of STIM1 as evident
from western blot (Figure 9D). Simultaneously, we have also
examined the changes in expression of CHOP, and pFAK after
the treatment with Phemindole (Figure 9D). All these findings
thus cumulatively suggested that this newly synthesized indole
derivative Phemindole could also effectively reduce in vivo solid
tumor growth by lowering down STIM1 expression levels in mice
models.
Validation of Tumor Suppressive Effect
Phemindole in Ex Ovo Model
The chick embryo model has long been used for the investigation
of oncogenesis and angiogenesis (Ossowski and Reich, 1980).
Interestingly, the chick embryo have served as a very useful
model for the investigation of tumor cell apoptosis due to its
advantages of being a natural immunodeficient host allowing easy
transplantation and a suitable in vivo experimental system as
validated by many studies (Gordon and Quigley, 1986). Chick
embryos, when inoculated with 1 × 105 MDAMB-231 cells onto
their CAM, primary tumors were developed within 12 days
(Figure 9E). Photographs from Figure 9E evidently display
suppression of tumor formation on treatment with Phemindole
at a dose of 10 µM.
Comparative Assessment of In Vivo
Hepato and Nephro Toxicity of
Phemindole
In order to analyze the tumor sections histopathologically, H&E
staining was performed. It was observed that tissue sections
of the control tumors revealed higher infiltration and poorly
differentiated structures. No such cellular/tissue damages were
observed in Phemindole treated sets (Figure 10A). Immuno histo
Chemistry study against STIM1 antibody also revalidated our
findings (Figure 10B). Histopathological data also showed that
Phemindole delivered a complete protection from the damage
produced by the tumor to the kidney and liver (Figure 10C).
It is quite well known that Aspartate aminotranferases (SGOT),
alanine aminotransferases (SGPT), and Urea, Createnine (ALP)
are the enzymes found in liver and kidney which corresponds
to the biochemical indices of liver function tests and kidney
functions tests. Any changes in the levels of these enzymes
may contribute to liver and kidney injury status. In order to
evaluate whether the Phemindole caused any hepatotoxicity or
nephrotoxicity the serum biochemical parameters such as SGPT,
SGOT, Urea and Creatinine were measured from the serum
collected from blood of both the treated and untreated sets
of mice. We observed that activities of these enzymes in the
serum were significantly altered in untreated tumor bearing
mice sets as compared normal untreated animals. However,
Phemindole provided a complete safeguard to the liver and
kidney restoring to the normal level (Figure 10D). In conclusion,
our experimental set up portrays that the Phemindole proves
to be a very effective therapeutic option against TNBC cells as
summarized in Figure 10E.
DISCUSSION
One of the deadliest aspects of TNBC cells is their aggressive
nature and high metastatic ability thereby rendering them
resistant to most commonly available therapies (Minami
et al., 2011). Therefore by elucidating the critical molecular
mechanisms of TNBC and targeting these mechanisms with
alternative therapeutic agents may help to take significant
clinical strides in the coming years. It has been acknowledged
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FIGURE 6 | Continued
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FIGURE 6 | Continued
Inhibitions of STIM1 mimics the effects of Phemindole and over expression of STIM1 showed opposite effect. (A) Ca2+ imaging was performed in
control, in the presence of SKF 96365 (SOCE inhibitor) and STIM1 si-RNA treated MDAMB-231 cells. Analog plots of the fluorescence ratio (340/380) of the cells
were shown. Knockdown of STIM1 protein was confirmed by western blot analysis (Inset) (B) Quantification (mean ± SD) of fluorescence ratio (340/380). ∗P < 0.05
versus control. (C) Bar diagram showed MTT assay under SKF 96365, STIM1 si-RNA, treated conditions for 24 h in MDAMB231 cells. (D) STIM1 protein levels were
restored by Transfection of STIM1 clones and also other protein levels were measured in presence and absence of Phemindole in STIM1 transfected cells by western
blot (left panel). Quantification of band intensity in respect to loading control was shown in bar diagram (left panel). Blots are representative of three independent
experiments and quantifications are indicated by bar diagram. Values were normalized by intensity of loading control. (E) Fura-2 Ca2+ imaging showing the results of
a quantitative analysis of Ca2+ content (or Ca2+ release in after Tg treatment) and Ca2+ influx during SOCE as mentioned previously. Values are the mean ± SEM
for all cells in plates ∗p < 0.05 versus control group. (F) Bar diagram represented the cell proliferation pattern of STIM1 over expressed MDAMB-231 cells in
presence of Phemindole treatment. Each bar gives the mean ± SEM of three separate experiments. ∗,∗∗,∗∗∗,# indicate p < 0.05, p < 0.01, p < 0.0005, p > 0.05
respectively versus untreated or control group.
FIGURE 7 | Anti-mitotic property of Phemindole on MDAMB-231 cells. (A) Phemindole induced cell cycle arrest in the G2/M phase in MDA-MB cells. Cells
were treated for 24 h with Phemindole at different concentrations as indicated, cells were processed for cell cycle analysis (left panel). Quantified Graphical plot on
the right panel. (B–D) Western blot analysis was performed to check the expression of cell cycle-associated proteins in presence of Phemindole in different
concentration; β-actin was used as a loading control. Quantification of band intensity in respect to loading control was shown in bar diagram (lower panels). Blots are
representative of three independent experiments and quantifications are indicated by bar diagram. Values were normalized by intensity of loading control. ∗,∗∗,∗∗∗,#
indicate p < 0.05, p < 0.01, p < 0.0005, p > 0.05 respectively versus untreated or control group.
that STIM/Orai-mediated SOCE facilitates tumor growth and
metastasis in different types of cancer and also plays a significant
role in drug resistant breast cancer cells (Schmidt et al., 2014).
Furthermore, STIM1 or Orai1 was found to be over expressed
in tumor tissues when compared with pre-cancerous tissues
in breast cancer patients (Yang et al., 2009). Knockdown or
pharmacological inhibition of STIM1–Orai1 can thus effectively
confine the growth and metastasis of breast cancer (Xie
et al., 2015). Various mechanisms have been implicated in the
induction of SOCE mediated apoptosis, however, none of them
seemed to be significantly operative in TNBC cells thereby
rendering them significantly resistant to apoptosis induced by
the non-specific SOCE inhibitors. Nevertheless, SOCE inhibitor
mediated apoptosis was found to be readily triggered in the
TNBC cells on simultaneous activation of ER stress and ROS
mediated pathway. These findings thereby suggested that the
coupled action of ER stress and ROS with SOCE inhibitor
may significantly enhance the anti proliferative as well as anti
metastatic potential of SOCE inhibitor in TNBC cells.
In the current study we have attempted to investigate the
anti-carcinogenic property of Phemindole, a synthetic analog
of 3,3′di Indolyl Methane[DIM]. Phemindole was found to be
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FIGURE 8 | Continued
Phemindole also shows anti migratory property on TNBC cells. (A) The rate of migration of MDAMB-231 breast cancer cells, on treatment with different
concentration of Phemindole (1, 2.5, 5 µM) at 0 and 24 h as determined from bidirectional wound healing assay (left panel). Bar diagram representation of the
percentage of migration of MDAMB- 231 cells at 0 and 24 h on treatment with different concentration of Phemindole (1, 2.5, 5 µM) (right panel). (B) Phase contrast
images showing the stained MDAMB-231cells as obtained from the trans well migration assay in control and Phemindole treated cells at different concentrations of
Phemindole (1, 2.5, 5 µM) (left panel). Percentage of cell migration of MDAMB-231 cells was represented by bar chart under the aforementioned conditions (right
panel). (C) Western blot analysis determining the changes in pFAK expression levels of the aforementioned set (upper panel). Quantification of band intensity in
respect to loading control was shown in bar diagram (lower panels). Blots are representative of three independent experiments and quantifications are indicated by
bar diagram. Values were normalized by intensity of loading control. (D) Immunofluorescence images showing decreased expression of p-FAK in the cytosolic region
in response to Phemindole treatment in MDAMB-231 cells. Anti-p-FAK secondary antibody was FITC tagged (green) and nuclei were stained with DAPI (blue) (left
panel). Corrected Fluoroscence intensity of p-FAK protein was quantified and represented as bar diagram (right panel). Pictures showed representative cells of each
population and were representative of three independent experiments. Values are mean ± SEM of three independent experiments in each case or representative of
typical experiment. ∗,∗∗,∗∗∗,# indicate p < 0.05, p < 0.01, p < 0.0005, p > 0.05 respectively versus untreated or control group.
a potent inducer of apoptosis in the TNBC cells. But a clear
understanding of the exact molecular targets of Phemindole is
required to specifically designate the exact dose of Phemindole
required for chemotherapeutic use in future. The present study
thus furnishes multiple evidences to confirm that Phemindole
directed multiple signaling pathways culminates to apoptosis, cell
cycle retardation and finally inhibition of migration of MDAMB-
231 cells.
The present study demonstrated that Phemindole in a
dose dependent manner induced cell death and prevented
cell proliferation. Interestingly, Phemindole was found to
significantly alter the level of ER calcium release in cytosol
as well as suppress the SOCE activation due to ER store
depletion. Several studies have already shown that alternation
in SOCE was one of the major reasons for transformation
of malignancy as well as apoptotic resistance phenomena
in different type of premalignant cells (Prevarskaya et al.,
2011). STIM1 and Orai1 are the key players of SOCE. Our
observation revealed that Phemindole treatment altered SOCE
by down regulating the expression of STIM1 in MDAMB-
231 cells. On the other hand, the other partner protein
Orai1 expression level remained unchanged in presence of
Phemindole. However, the STIM1- Orai1 interaction was also
turned down in plasma membrane. This type of interaction is
responsible for calcium entry in response to store depletion.
Our data incarnate the recent study which indicated that STIM1
also may be responsible in the development of aggressive
nature of MDAMB-231 (Bergmeier et al., 2013). Other studies
have also shown that knockdown of SOCE related protein
significantly blocked the proliferation and migration of cancer
cell (Prevarskaya et al., 2011; Bergmeier et al., 2013). In these
respect our data is quite promising since Phemindole decreased
STIM1 expression and induced cell death by weakening
SOCE in TNBC cells. Using pharmacological Inhibitor of
SOCE SKF-96365 we also revalidated the effect of Phemindole
mediated SOCE inhibition in MDAMB-231 cells. Whereas,
when we over expressed STIM1 protein in Phemindole treated
cells, it restored SOCE and the death percentage was also
reduced significantly in comparison with Phemindole treated
empty vector transfected control MDAMB-231 cells. These
results implied that Phemindole targets STIM1 to alter the
SOCE of TNBC cells for undertaking its anti-carcinogenic
activity.
However, we also found that Phemindole regulates various
other mechanisms including ER stress and ROS generation. Stress
in ER was produced by ER Ca2+ depletion due to the blocking
of SOCE by Phemindole. It has been suggested that this change
in ER Ca2+ homeostasis may cause improper protein folding in
the ER Lumen and cause ER stress (Zhang and Kaufman, 2008).
Consistent with this, we found that significant ER stress was
induced by Phemindole in MDAMB-231 cells which was evident
from the upregulation of the ER stress related marker proteins
GRP78/Bip and CHOP/GADD153.
Hence, it is suggested that Phemindole which can affect both
SOCE and ER stress could be a new chemotherapeutic strategy
in the treatment of TNBC cells. Furthermore our findings
highlighted that Phemindole treatment potentiated the ER stress
mediated pathway. However, ROS scavenger NAC co-treatment
with Phemindole also decreased the percentage of death cell but
it cannot completely revert back the effect of Phemindole in
MDAMB-231 cells. The STIM1 over expression reverted back
the Phemindole-mediated SOCE alternation and cell viability.
Our data thus suggested that Phemindole caused ROS generation
and activated the mitochondrial apoptotic cascade and also
simultaneously targeted STIM1 mediated SOCE suppression
and depleted ER store leading to ER Stress-mediated apoptotic
cell death in TNBC cells. Our results also highlighted that
Phemindole significantly arrested cell cycle progression and
retardate migration of the MDAMB-231 cells which further
culminates in producing an overall anti-tumorigenic effect
against TNBC cells. Our in vitro data were also re-evaluated by
our in vivo results where significant tumor growth restriction
was observed in both 4T1 bearing BALB/c mice models as
well as in the ex ovo models thereby clearly highlighting
the importance of Phemindole as a potential anti-tumorigenic
agent.
CONCLUSION
Store Operated Calcium Entry is effectively engaged in the
MDAMB-231 cell growth and differentiation. Phemindole
treatment attenuated SOCE and induced ER stress mediated
cell death. Simultaneously Phemindole exerted ROS mediated
mitochondrial membrane disruption. Coupling effect of these
two pathways caused huge percentage of TNBC cell death after
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FIGURE 9 | Validation of tumor suppressive effect of Phemindole in ex ovo model and in vivo breast tumor in BALB/c mice model. (A) Photograph of
4T1 cell induced tumors from BALB/c mice and excised tumors from untreated or treated with Phemindole 10 mg/kg and 15 mg/kg body weight. (B) Weight of the
excised tumors from control and Phemindole treated sets were measured, analyzed and represented in the form of bar graph. (C) Graphical representation of the
changes in the tumor volume of Phemindole treated and untreated mice for a period of 8 weeks. (D) Western blot analysis depicting the changes in the expression
level of different protein level in the untreated and Phemindole treated tumors. β-actin was used as internal loading control (upper panel). Blots are representative of
three independent experiments and quantifications are indicated by Bar diagram (lower panel). Values were normalized by intensity of loading control. (E) Ex ovo
model showing tumor regression due to Phemindole treatment at 3, 6, and 12 days. Values are mean ± SEM of three independent experiments in each case or
representative of typical experiment. ∗∗P < 0.01, and ∗∗∗P < 0.001.
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FIGURE 10 | Assessment of toxicity of Phemindole. (A) 4T1 induced tumors excised from the aforementioned sets were analyzed histopathologically using
eosin haematoxylin staining and phase contrast images were captured. (B) Immuno-histochemical analysis of the excised tumors from the untreated and
Phemindole treated sets using anti-STIM1 antibody (left panel). Corrected Fluorescence intensity of STIM1 protein was quantified and represented as bar diagram
(right panel). (C) Histological sections of liver and kidney from the animals were stained with haematoxylin and counter-stained with eosin and microscopically
analyzed for histopathologically examinations of tissue toxicity like cellular damage and vacuolization. (D) Blood was collected after sacrifice the mice from control,
untreated tumor and Phemindole treated sets and subsequent Liver function test and Kidney Function Test were performed. All measurements of three groups were
repeated at least three times, Values are mean ± SEM of three independent experiments in each case or representative of typical experiment. ∗∗∗P < 0.001, (E)
Schematic diagram depicting the detailed molecular mechanisms of antitumorogenic activity of Phemindole against triple negative breast cancer cells.
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Phemindole treatment. To the best of our knowledge, this is
the first report that Phemindole induces ER stress mediated
apoptosis in TNBC cells by targeting SOCE through down-
regulation of STIM1 protein. Phemindole also plays a significant
role in controlling cell cycle progression and migration of
TNBC cells. Thus further study with this novel molecule may
help to bring about a new era in chemotherapeutic drug
development.
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